Structural M&A and financing are important issues in the biotechnology, pharmaceuticals and medical devices industries. Many companies in these sectors consider either approaching venture capital or private equity funds or entering the public markets as a path to capital and liquidity.
Vinge is the leading Swedish law firm in private and public M&A and capital raising representing both companies and investors. Our services range from assistance in traditional M&A deals, private-equity funded buy-outs and venture capital funding to assistance in IPOs and other equity capital market transactions. Over the past 20 years, we have handled the most transactions and the highest-value projects in the Swedish market. We give qualified advice on company law and legal matters regarding capital markets. As a leading team in this area, we have in-depth knowledge of the regulatory system governing stock market transactions and can add value in both strategic and structural matters.
With significant transactional experience and specific knowledge of the commercial conditions in the life sciences & health industries, Vinge’s specialists can perform transactions quickly, efficiently and to the highest standard.